Clinical trial NCT04623710: Study of ALXN2050 in Participants With Renal Impairment
Official title: A Phase 1, Open-Label, Multiple-Dose, Parallel Study to Determine the Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ALXN2050 in Adult Participants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Renal Impairment
Healthy
Keywords: Factor D Inhibitor
Pharmacokinetics
Pharmacodynamics
Safety
ALXN2050
Lead sponsor: Alexion Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2020-11-10
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study will investigate the impact of impaired renal function on the plasma pharmacokinetics of ALXN2050 in order to provide dosing recommendations for future indications in individuals with impaired renal function.

Detailed description: The study will initiate (Part 1) with participants with severe impaired renal function (Cohort 1) and their matched healthy control participants (Cohort 4). Following data review, the study may proceed (Part 2) with participants with moderate (Cohort 2) and mild (Cohort 3) impaired renal function if deemed necessary.

Eligibility criteria: Inclusion Criteria:

1. Body weight must be at least 50.0 kilograms (kg) and body mass index (BMI) within the range of 18.0 - 40.0 kg/meter squared (m\^2) (inclusive) at the time of signing the informed consent.
2. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
3. Must agree to receive prophylactic antibiotics to mitigate the potential risk of meningococcal infection.

   Participants with Impaired Renal Function
4. Aside from impaired renal function, sufficiently healthy for study participation based upon medical history, physical examination, neurological examination, laboratory tests, vital signs, and electrocardiograms (ECGs).
5. A clinical diagnosis of impaired stable renal function.
6. No clinically significant change in renal status at least 1 month prior to first dose of study intervention and is not currently or has not previously been on hemodialysis or did not have any history of peritoneal dialysis.
7. Stable creatinine clearance.
8. Must be on a stable medication regimen. Concomitant medications must be approved by Alexion unless presented in the list of common concurrent medications for participants with impaired renal function.

   Matched Healthy Control Participants with Normal Renal Function
9. Must match the sex and the race (similar ratio of white and non-white) of participants with impaired renal function, and at screening, age must be within ± 10 years and BMI must be within ± 20% of the matching participants with impaired renal function
10. Healthy as determined by medical evaluation, including medical history, physical examination, neurological examination, laboratory tests, vital signs, and ECGs, and who possess a baseline eGFR ≥ 90 mL/min/1.73 m\^2, based on MDRD equation at screening.

Exclusion Criteria:

1. History or presence of seizures, head injury, head trauma, or any other brain disorder.
2. History of procedures that could alter absorption or excretion of orally administered drugs.
3. History of meningococcal infection or a first-degree relative with a history of meningococcal infection.
4. Body temperature ≥38.0°Celcius at screening or check-in or history of febrile illness or other evidence of infection, systemic or otherwise, within 14 days prior to the first dose of study intervention.
5. Participants with CH50 results outside the reference ranges at screening, unless approved by Alexion
6. Significant blood loss or donation of blood within 3 months prior to the first dose of study intervention, donation of plasma within 30 days prior to the first dose of study intervention, receipt of blood products within 6 months prior to first dose of study intervention, or receipt of a vaccine within 30 days prior to the first dose of study intervention.
7. Current enrollment or past participation within the last 30 days (or 5 half-lives, whichever is longer) prior to the first dose of study intervention in the current clinical study or any other clinical study involving an investigational study intervention or any other type of medical research.
8. History or presence of drug or alcohol abuse within 1 year prior to the first dose of study intervention, current tobacco user, or positive results for alcohol and/or drug screen at screening or check-in.
9. Pregnant or lactating.
10. Does not produce sufficient urine output to permit urine sampling at screening and/or check-in or has a history of urinary incontinence prior to check-in.
11. History of kidney transplant or actively on a transplant waiting list prior to check-in.
12. Any acute or chronic non-renal condition prior to check-in that would limit the participant's ability to complete or participate in this clinical study.

Primary outcomes:
measure: Area Under The Concentration-time Curve From Time 0 To The 12-hour Time Point (AUC0-12) Of Plasma ALXN2050 After Steady-state
timeFrame: Up to 72 hours postdose
measure: Area Under The Concentration-time Curve Calculated To The Last Observable Concentration At Time t (AUCt) Of Plasma ALXN2050 After Steady-state
timeFrame: Up to 72 hours postdose
measure: Maximum (Peak) Steady-state Plasma Concentration (Cmax,ss) Of Plasma ALXN2050
timeFrame: Up to 72 hours postdose
measure: Time To Reach Maximum (Peak) Plasma Concentration Following ALXN2050 Administration At Steady-state (Tmax,ss)
timeFrame: Up to 72 hours postdose
Secondary outcomes:
measure: Change From Baseline In Complement Factor D Concentration At 24, 48, And 72 Hours Postdose
timeFrame: Baseline, 24, 48, and 72 hours postdose
measure: Change From Baseline In Plasma b Fragment Of Complement Factor B Concentration
timeFrame: Baseline, up to 72 hours postdose
measure: Change From Baseline In Complement Alternative Pathway Activity
timeFrame: Baseline, up to 72 hours postdose
measure: Number Of Participants Receiving ALXN2050 With Treatment-emergent Adverse Events
timeFrame: Day 1 (postdose) through follow-up (30 [+/- 2] days after last study drug administration)]
Other outcomes:
Locations:
city: Hialeah
country: United States
facility: Clinical Trial Site
state: Florida
city: Orlando
country: United States
facility: Clinical Trial Site
state: Florida
Study officials:
References: